How A 29-Year-Old Chemist Proved That Even In England Startups Can Thrive

Keith Davies has made Chemical Design a world leader in molecular modeling LONDON—By now we’ve all seen the numbers and heard the gloomy forecasts. Science in the United Kingdom is suffering from a dearth of funding, incentives, and political clout. The lack of commitment to R&D on the part of both the private and public sectors in Britain has sparked an alarming emigration of scientists and high-tech entrepreneurs. But for every rule there is an exception, and Keith Davies is

Written byJohn Stansell
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

LONDON—By now we’ve all seen the numbers and heard the gloomy forecasts. Science in the United Kingdom is suffering from a dearth of funding, incentives, and political clout. The lack of commitment to R&D on the part of both the private and public sectors in Britain has sparked an alarming emigration of scientists and high-tech entrepreneurs.

But for every rule there is an exception, and Keith Davies is the man to prove that even in luck, England, the age-old recipe for entrepreneurial success remains a constant. With a good idea, a little funding, a lot of commitment, and an indeterminate amount of luck, the “little guy”—yes, even a chemist—can build a company and make a mark in the world.

Davies, just 29 years old,is CEO and founder of Chemical Design Ltd., the small company that in five short years has progressed from a one-man startup—funded with $145 of his own ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies